President Trump’s latest healthcare proposal could have the effect of raising out-of-pocket drug costs for some while lowering them for others; FDA Commissioner Scott Gottlieb said it is shocking to him that the rate of young people addicted to using e-cigarettes, or vaping, had reached levels at which FDA-approved methods for quitting e-cigarettes could be necessary; "Medicare for More,” not Medicare for All, is likely to emerge as Democrats jockey for 2020 with a watered-down version of universal health care.
President Trump’s latest healthcare proposal could have the effect of raising out-of-pocket drug costs for some while lowering them for others, The New York Times reported. The proposal would apply to health insurance plans sold under the Affordable Care Act. Under the proposal, insurers would not have to count the full amount of a consumer’s co-payment for a brand-name drug toward the annual limit on cost-sharing; plans would only count the smaller amount that would be charged for a generic version of the drug.FDA Commissioner Scott Gottlieb said it is shocking to him that the rate of young people addicted to using e-cigarettes, or vaping, had reached levels at which FDA-approved methods for quitting e-cigarettes could be necessary, The Hill reported. He said the problem stems from the explosion in availability and popularity of e-cigarettes over the past year, in part fueled by the availability and convenience of JUUL brand e-cigarettes. Those factors have caused vaping rates to nearly double among high school students between 2017-2018.“Medicare for More,” not Medicare for All, is likely to emerge as Democrats jockey for 2020 with a watered-down version of universal health care, Politico reported. The move is stirring friction within the party's empowered left wing, which has panned any attempt to water down the progressive dream of a single-payer system. But Democrats have introduced 8 plans that range from modest reforms to something just short of full Medicare for All.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More